<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27170066</PMID><DateCompleted><Year>2018</Year><Month>03</Month><Day>27</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><PubDate><Year>2016</Year><Month>May</Month><Day>12</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>A Modular Vaccine Development Platform Based on Sortase-Mediated Site-Specific Tagging of Antigens onto Virus-Like Particles.</ArticleTitle><Pagination><StartPage>25741</StartPage><MedlinePgn>25741</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">25741</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/srep25741</ELocationID><Abstract><AbstractText>Virus-like particles (VLPs) can be used as powerful nanoscale weapons to fight against virus infection. In addition to direct use as vaccines, VLPs have been extensively exploited as platforms on which to display foreign antigens for prophylactic vaccination and immunotherapeutic treatment. Unfortunately, fabrication of new chimeric VLP vaccines in a versatile, site-specific and highly efficient manner is beyond the capability of traditional VLP vaccine design approaches, genetic insertion and chemical conjugation. In this study, we described a greatly improved VLP display strategy by chemoenzymatic site-specific tailoring antigens on VLPs surface with high efficiency. Through the transpeptidation mediated by sortase A, one protein and two epitopes containing N-terminal oligoglycine were conjugated to the LPET motif on the surface of hepatitis B virus core protein (HBc) VLPs with high density. All of the new chimeric VLPs induced strong specific IgG responses. Furthermore, the chimeric VLPs with sortase A tagged enterovirus 71 (EV71) SP70 epitope could elicit effective antibodies against EV71 lethal challenging as well as the genetic insertion chimeric VLPs. The sortase A mediated chemoenzymatic site-specific tailoring of the HBc VLP approach shows great potential in new VLP vaccine design for its simplicity, site specificity, high efficiency, and versatility.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Shubing</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Unit of Herpesvirus and Molecular Virology, Key Laboratory of Molecular Virology &amp;Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai 200031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xuan</LastName><ForeName>Baoqin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Unit of Herpesvirus and Molecular Virology, Key Laboratory of Molecular Virology &amp;Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai 200031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Xiaohua</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Unit of Vaccinology and Antiviral Strategies, Key Laboratory of Molecular Virology &amp;Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai 200031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Zhong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Unit of Vaccinology and Antiviral Strategies, Key Laboratory of Molecular Virology &amp;Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai 200031, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>Zhikang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Unit of Herpesvirus and Molecular Virology, Key Laboratory of Molecular Virology &amp;Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, University of the Chinese Academy of Sciences, Shanghai 200031, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>05</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014758">Viral Core Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006509" MajorTopicYN="N">Hepatitis B</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007114" MajorTopicYN="N">Immunization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014758" MajorTopicYN="N">Viral Core Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014771" MajorTopicYN="N">Virion</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000648" MajorTopicYN="N">ultrastructure</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>5</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>5</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>5</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27170066</ArticleId><ArticleId IdType="pmc">PMC4864371</ArticleId><ArticleId IdType="doi">10.1038/srep25741</ArticleId><ArticleId IdType="pii">srep25741</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ashley C. E. et al. Cell-Specific Delivery of Diverse Cargos by Bacteriophage Ms2 Virus-Like Particles. ACS Nano 5, 5729&#x2013;5745 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3144304</ArticleId><ArticleId IdType="pubmed">21615170</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z., Tang L. J., Zhang X. B., Jiang J. H. &amp; Tan W. Aptamer-Modified Nanodrug Delivery Systems. ACS Nano 5, 7696&#x2013;7699 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3245875</ArticleId><ArticleId IdType="pubmed">22023403</ArticleId></ArticleIdList></Reference><Reference><Citation>Atanasova P. et al. Genetically Improved Monolayer-Forming Tobacco Mosaic Viruses to Generate Nanostructured Semiconducting Bio/Inorganic Hybrids. Langmuir 31, 3897&#x2013;3903 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25768914</ArticleId></ArticleIdList></Reference><Reference><Citation>Grgacic E. V. &amp; Anderson D. A. Virus-Like Particles: Passport to Immune Recognition. Methods 40, 60&#x2013;65 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7128828</ArticleId><ArticleId IdType="pubmed">16997714</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig C. &amp; Wagner R. Virus-Like Particles-Universal Molecular Toolboxes. Curr. Opin. Biotechnol. 18, 537&#x2013;545 (2007).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7126091</ArticleId><ArticleId IdType="pubmed">18083549</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachmann M. F. &amp; Jennings G. T. Vaccine Delivery: A Matter of Size, Geometry, Kinetics and Molecular Patterns. Nat. Rev. Immunol. 10, 787&#x2013;796 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20948547</ArticleId></ArticleIdList></Reference><Reference><Citation>Plummer E. M. &amp; Manchester M. Viral Nanoparticles and Virus-Like Particles: Platforms for Contemporary Vaccine Design. Wiley. Interdiscip. Rev. Nanomed. Nanobiotechnol. 3, 174&#x2013;196 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7169818</ArticleId><ArticleId IdType="pubmed">20872839</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Barwani F., Donaldson B., Pelham S. J., Young S. L. &amp; Ward V. K. Antigen Delivery by Virus-Like Particles for Immunotherapeutic Vaccination. Ther. Deliv. 5, 1223&#x2013;1240 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25491672</ArticleId></ArticleIdList></Reference><Reference><Citation>Barcena J. &amp; Blanco E. Design of Novel Vaccines Based on Virus-Like Particles or Chimeric Virions. Subcell. Biochem. 68, 631&#x2013;665 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23737067</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y. et al. Generation of Chimeric HBc Proteins with Epitopes in E.Coli: Formation of Virus-Like Particles and a Potent Inducer of Antigen-Specific Cytotoxic Immune Response and Anti-Tumor Effect in Vivo. Cell. Immunol. 247, 18&#x2013;27 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17707782</ArticleId></ArticleIdList></Reference><Reference><Citation>Molino N. M., Anderson A. K., Nelson E. L. &amp; Wang S. W. Biomimetic Protein Nanoparticles Facilitate Enhanced Dendritic Cell Activation and Cross-Presentation. ACS Nano 7, 9743&#x2013;9752 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893022</ArticleId><ArticleId IdType="pubmed">24090491</ArticleId></ArticleIdList></Reference><Reference><Citation>Venter P. A. et al. Multivalent Display of Proteins on Viral Nanoparticles Using Molecular Recognition and Chemical Ligation Strategies. Biomacromolecules, 12, 2293&#x2013;2301 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3114102</ArticleId><ArticleId IdType="pubmed">21545187</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel K. G. &amp; Swartz J. R. Surface Functionalization of Virus-Like Particles by Direct Conjugation Using Azide-Alkyne Click Chemistry. Bioconjug. Chem. 22, 376&#x2013;387 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5437849</ArticleId><ArticleId IdType="pubmed">21355575</ArticleId></ArticleIdList></Reference><Reference><Citation>Jegerlehner A. et al. A Molecular Assembly System That Renders Antigens of Choice Highly Repetitive for Induction of Protective B Cell Responses. Vaccine 20, 3104&#x2013;3112 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12163261</ArticleId></ArticleIdList></Reference><Reference><Citation>Spohn G. et al. Active Immunization with Il-1 Displayed on Virus-Like Particles Protects from Autoimmune Arthritis. Eur. J. Immunol. 38, 877&#x2013;887 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18253928</ArticleId></ArticleIdList></Reference><Reference><Citation>Freer G. et al. Dissection of Seroreactivity against the Tryptophan-Rich Motif of the Feline Immunodeficiency Virus Transmembrane Glycoprotein. Virology 322, 360&#x2013;369 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15110533</ArticleId></ArticleIdList></Reference><Reference><Citation>Jegerlehner A. et al. Regulation of IgG Antibody Responses by Epitope Density and CD21-Mediated Costimulation. Eur. J. Immunol. 32, 3305&#x2013;3314 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12555676</ArticleId></ArticleIdList></Reference><Reference><Citation>Pumpens P. &amp; Grens E. HBV Core Particles as a Carrier for B Cell/T Cell Epitopes. Intervirology, 44, 98&#x2013;114 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11509871</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilangovan U., Ton-That H., Iwahara J., Schneewind O. &amp; Clubb R. T. Structure of Sortase, the Transpeptidase That Anchors Proteins to the Cell Wall of Staphylococcus Aureus. Proc. Natl. Acad. Sci. USA 98, 6056&#x2013;6061 (2001).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC33421</ArticleId><ArticleId IdType="pubmed">11371637</ArticleId></ArticleIdList></Reference><Reference><Citation>Potzsch S. et al. Stamminger, T.; Martin-Parras, L.; Mach, M., and Winkler, T.H. B Cell Repertoire Analysis Identifies New Antigenic Domains on Glycoprotein B of Human Cytomegalovirus Which Are Target of Neutralizing Antibodies. Plos Pathog. 7, e1002172 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3154849</ArticleId><ArticleId IdType="pubmed">21852946</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye X. et al. Chimeric Virus-Like Particle Vaccines Displaying Conserved Enterovirus 71 Epitopes Elicit Protective Neutralizing Antibodies in Mice through Divergent Mechanisms. J. Virol. 88, 72&#x2013;81 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3911748</ArticleId><ArticleId IdType="pubmed">24131712</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker A., Skamel C. &amp; Nassal M. Splitcore: An Exceptionally Versatile Viral Nanoparticle for Native Whole Protein Display Regardless of 3d Structure. Sci. Rep. 1, 5 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3216493</ArticleId><ArticleId IdType="pubmed">22355524</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian B. X. &amp; Eriksson L. A. Catalytic Mechanism and Roles of Arg197 and Thr183 in the Staphylococcus Aureus Sortase a Enzyme. J. Phys. Chem. B. 115, 13003&#x2013;13011 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21950672</ArticleId></ArticleIdList></Reference><Reference><Citation>Guimaraes C. P. et al. Site-Specific C-Terminal and Internal Loop Labeling of Proteins Using Sortase-Mediated Reactions. Nat. Protoc. 8, 1787&#x2013;1799 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3943461</ArticleId><ArticleId IdType="pubmed">23989673</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen I., Dorr B. M. &amp; Liu D. R. A General Strategy for the Evolution of Bond-Forming Enzymes Using Yeast Display. Proc. Natl. Acad. Sci. USA 108, 11399&#x2013;11404 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3136257</ArticleId><ArticleId IdType="pubmed">21697512</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon K. Y., Tan W. S., Tey B. T., Lee K. W. &amp; Ho K. L. Native Agarose Gel Electrophoresis and Electroelution: A Fast and Cost-Effective Method to Separate the Small and Large Hepatitis B Capsids. Electrophoresis 34, 244&#x2013;252 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23161478</ArticleId></ArticleIdList></Reference><Reference><Citation>Schagger H. Tricine-Sds-Page. Nat. Protoc. 1, 16&#x2013;22 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">17406207</ArticleId></ArticleIdList></Reference><Reference><Citation>Swee L. K. et al. Sortase Mediated Modification of Alphadec205 Affords Optimization of Antigen Presentation and Immunization against a Set of Viral Epitopes. Proc. Natl. Acad. Sci. USA 110, 1428&#x2013;1433 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3557095</ArticleId><ArticleId IdType="pubmed">23297227</ArticleId></ArticleIdList></Reference><Reference><Citation>Spindler N. et al. Characterization of a Discontinuous Neutralizing Epitope on Glycoprotein B of Human Cytomegalovirus. J. Virol. 87, 8927&#x2013;8939 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3754028</ArticleId><ArticleId IdType="pubmed">23740990</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin H. et al. A beta-HBc Virus-Like Particles Immunization without Additional Adjuvant Ameliorates the Learning and Memory and Reduces A beta Deposit in PDAPP Mice. Vaccine 32, 4450&#x2013;4456 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24962758</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhanasooraj D., Kumar R. A. &amp; Mundayoor S. Vaccine Delivery System for Tuberculosis Based on Nano-Sized Hepatitis B Virus Core Protein Particles. Int J Nanomedicine 8, 835&#x2013;843 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3592552</ArticleId><ArticleId IdType="pubmed">23486691</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin Y. et al. Chimeric Hepatitis B Virus Core Particles Carrying an Epitope of Anthrax Protective Antigen Induce Protective Immunity against Bacillus Anthracis. Vaccine 26, 5814&#x2013;5821 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18786589</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazaks A., Balmaks R., Voronkova T., Ose V. &amp; Pumpens P. Melanoma Vaccine Candidates from Chimeric Hepatitis B Core Virus-Like Particles Carrying a Tumor-Associated Mage-3 Epitope. Biotechnol. J. 3, 1429&#x2013;1436 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18956370</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregson A. L. et al. Phase I Trial of an Alhydrogel Adjuvanted Hepatitis B Core Virus-Like Particle Containing Epitopes of Plasmodium Falciparum Circumsporozoite Protein. Plos One 3, e1556 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2216688</ArticleId><ArticleId IdType="pubmed">18253503</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambuhl P. M. et al. A Vaccine for Hypertension Based on Virus-Like Particles: Preclinical Efficacy and Phase I Safety and Immunogenicity. J. Hypertens. 25, 63&#x2013;72 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17143175</ArticleId></ArticleIdList></Reference><Reference><Citation>Chackerian B., Rangel M., Hunter Z. &amp; Peabody D. S. Virus and Virus-Like Particle-Based Immunogens for Alzheimer&#x2019;s Disease Induce Antibody Responses against Amyloid-Beta without Concomitant T Cell Responses. Vaccine 24, 6321&#x2013;6331 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16806604</ArticleId></ArticleIdList></Reference><Reference><Citation>Speiser D. E. et al. Memory and Effector Cd8 T-Cell Responses after Nanoparticle Vaccination of Melanoma Patients. J. Immunother. 33, 848&#x2013;858 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20842051</ArticleId></ArticleIdList></Reference><Reference><Citation>Pejawar-Gaddy S. et al. Generation of a Tumor Vaccine Candidate Based on Conjugation of a Muc1 Peptide to Polyionic Papillomavirus Virus-Like Particles. Cancer. Immunol. Immunother. 59, 1685&#x2013;1696 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3076734</ArticleId><ArticleId IdType="pubmed">20652244</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson D. J., Webb M. E. &amp; Turnbull W. B. Depsipeptide Substrates for Sortase-Mediated N-Terminal Protein Ligation. Nat. Protoc. 9, 253&#x2013;262 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24407354</ArticleId></ArticleIdList></Reference><Reference><Citation>Witte M. D. et al. Site-Specific Protein Modification Using Immobilized Sortase in Batch and Continuous-Flow Systems. Nat. Protoc. 10, 508&#x2013;516 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4757899</ArticleId><ArticleId IdType="pubmed">25719269</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynne S. A., Crowther R. A. &amp; Leslie A. G. The crystal structure of the human hepatitis B virus capsid. Mol. Cell 3, 771&#x2013;780. (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10394365</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>